{"title":"Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors.","authors":"C T Supuran, A Scozzafava","doi":"10.3109/14756360009040713","DOIUrl":null,"url":null,"abstract":"<p><p>Aromatic/heterocyclic sulfonamides generally act as strong inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). Here we report the unexpected finding that potent aromatic sulfonamide inhibitors of CA, possessing inhibition constants in the range of 10(-8)-10(-9) M (against all the isozymes), also act as efficient in vitro tumor cell growth inhibitors, with GI50 (molarity of inhibitor producing a 50% inhibition of tumor cell growth) values of 10 nM-35 microM against several leukemia, non-small cell lung cancer, ovarian, melanoma, colon, CNS, renal, prostate and breast cancer cell lines. The investigated compounds were sulfanilyl-sulfanilamide-, 4-thioureido-benzenesulfonamide- and benzene-1,3-disulfonamide-derivatives. The mechanism of antitumor action with these sulfonamides is unknown, but it might involve either inhibition of several CA isozymes (such as CA IX, CA XII, CA XIV) predominantly present in tumor cells, a reduced provision of bicarbonate for the nucleotide synthesis (mediated by carbamoyl phosphate synthetase II), the acidification of the intracellular milieu as a consequence of CA inhibition or uncoupling of mitochondria and potent CA V inhibition among others. A combination of several such mechanisms is also plausible. Optimization of such derivatives from the SAR point of view, might lead to the development of effective novel types of anticancer agents/therapies.</p>","PeriodicalId":15776,"journal":{"name":"Journal of enzyme inhibition","volume":"15 6","pages":"597-610"},"PeriodicalIF":0.0000,"publicationDate":"2000-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/14756360009040713","citationCount":"67","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of enzyme inhibition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/14756360009040713","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 67
Abstract
Aromatic/heterocyclic sulfonamides generally act as strong inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). Here we report the unexpected finding that potent aromatic sulfonamide inhibitors of CA, possessing inhibition constants in the range of 10(-8)-10(-9) M (against all the isozymes), also act as efficient in vitro tumor cell growth inhibitors, with GI50 (molarity of inhibitor producing a 50% inhibition of tumor cell growth) values of 10 nM-35 microM against several leukemia, non-small cell lung cancer, ovarian, melanoma, colon, CNS, renal, prostate and breast cancer cell lines. The investigated compounds were sulfanilyl-sulfanilamide-, 4-thioureido-benzenesulfonamide- and benzene-1,3-disulfonamide-derivatives. The mechanism of antitumor action with these sulfonamides is unknown, but it might involve either inhibition of several CA isozymes (such as CA IX, CA XII, CA XIV) predominantly present in tumor cells, a reduced provision of bicarbonate for the nucleotide synthesis (mediated by carbamoyl phosphate synthetase II), the acidification of the intracellular milieu as a consequence of CA inhibition or uncoupling of mitochondria and potent CA V inhibition among others. A combination of several such mechanisms is also plausible. Optimization of such derivatives from the SAR point of view, might lead to the development of effective novel types of anticancer agents/therapies.
芳香族/杂环磺酰胺通常是锌酶碳酸酐酶(CA,EC 4.2.1.1)的强抑制剂。在这里,我们报告了一个意想不到的发现,即具有 10(-8)-10(-9) M 抑制常数(对所有同工酶)的强效芳香族磺酰胺 CA 抑制剂也是高效的体外肿瘤细胞生长抑制剂、对几种白血病、非小细胞肺癌、卵巢癌、黑色素瘤、结肠癌、中枢神经系统癌、肾癌、前列腺癌和乳腺癌细胞系的 GI50 值(抑制剂摩尔浓度)为 10 nM-35 microM。所研究的化合物为硫酰磺酰胺、4-硫脲基苯磺酰胺和苯-1,3-二磺酰胺衍生物。这些磺胺类药物的抗肿瘤作用机制尚不清楚,但可能涉及抑制主要存在于肿瘤细胞中的几种 CA 同工酶(如 CA IX、CA XII 和 CA XIV)、减少为核苷酸合成提供碳酸氢盐(由氨基甲酰磷酸合成酶 II 介导)、CA 抑制或线粒体解偶联导致细胞内环境酸化以及有效抑制 CA V 等。将几种此类机制结合起来也是可行的。从 SAR 的角度对这些衍生物进行优化,可能会开发出有效的新型抗癌剂/疗法。